ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2839

BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation

Kichul Ko1, Denisse Yanez1, Natalya Kaverina1, Vladimir M. Liarski1, Yahui Peng2, Li Lan3, Stuart Perper4, Annette Schwartz5, Liz O'connor6, Andrew Souers7, Steven Elmore7, Lisa Olson5, Maryellen L. Giger3, Li Chun Wang4 and Marcus R. Clark1, 1Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, 2School of Electronic and Information Engineering, Beijing Jiaotong University, Beijing, China, 3Radiology, University of Chicago, Chicago, IL, 4Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 5AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 6Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 7AbbVie Inc, North Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Apoptosis, Confocal Microscopy, Inflammation, lupus nephritis and mouse model

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a manifestation of systemic autoimmunity while tubulointerstitial inflammation (TII) is associated with additional, in situ adaptive immune cell networks that might amplify local inflammation and tissue damage. Furthermore, patients with significant TII are more likely to fail conventional therapy and progress to renal failure. Therefore, understanding the mechanisms of in situ adaptive immunity in lupus TII might provide new therapeutic opportunities for treating LuN. In mice, BCL-2 family proteins are key regulators of immune cell apoptosis and forced expression of BCL-2 in B cells promotes lupus-like nephritis. We hypothesized that dysregulated expression of the BCL-2 family proteins in human LuN TII might contribute to local adaptive immunity, inflammation and disease pathogenesis.

Methods

Frozen renal biopsy specimens from 26 patients with SLE (ISN/RPS Class III, IV or V LuN), 10 mixed cellular renal allograft rejection (MR) biopsy specimens and tonsil samples from healthy subjects and kidneys from IFNα-induced NZB/W F1 lupus mice were stained with antibodies specific for CD20, CD4, BCL-2,  MCL-1 or BIM. Images were acquired using scanning laser confocal microscopy. IFNα-induced NZB/W F1 mice were treated daily with vehicle or 30 mg/kg of ABT-199 and analyzed for survival and the development of proteinuria. 

Results

A recently developed imaging tool (Science Translational Medicine 2014, 6:230) was used to quantify the frequency of CD20+ B and CD4+ T cells expressing the anti-apoptotic molecules BCL-2, MCL-1 and the pro-apoptotic molecule BIM.  In primary follicles of normal tonsils, both B and T cells frequently expressed BCL-2. However, upon entry into germinal centers (GC), BCL-2 was down-regulated and MCL-1 was induced. In marked contrast, in LuN and MR TII biopsies, the frequency of BCL-2+ cells was increased in B and T cells while MCL-1+ cells were rare. Observed differences between tonsil GC lymphocytes versus TII in LuN and MR for both BCL-2 and MCL-1 were highly significant (p<0.001). These expression differences were confirmed by laser capture microscopy coupled to qPCR. In contrast, the frequency of BIM+cells did not significantly vary among tissues. Consistent with these findings, BCL-2, but not MCL-1 expressing cells were detected in the inflamed kidney in IFNα-induced NZB/W F1 lupus mice. Furthermore, administration of ABT-199, a BCL-2 selective inhibitor, prevented the development of lupus nephritis by depleting intra-renal B and T cells in these animals. 

Conclusion

Frequent BCL-2, but not MCL-1, expressing cells were present in LuN, MR TII tissues and IFNα-induced NZB/W F1 lupus mice. Treatment of these mice with the BCL-2 selective inhibitor ABT-199 resulted in the loss of renal B and T cells and the preservation of renal function. These data indicate that BCL-2, which is dysregulated in TII, is an attractive therapeutic target in cases of lupus nephritis manifesting tubulointerstitial inflammation.


Disclosure:

K. Ko,
None;

D. Yanez,

AbbVie,

2;

N. Kaverina,

AbbVie,

2;

V. M. Liarski,
None;

Y. Peng,
None;

L. Lan,
None;

S. Perper,

AbbVie Inc.,

3;

A. Schwartz,

AbbVie Inc.,

3;

L. O’connor,

AbbVie Inc.,

3;

A. Souers,

AbbVie Inc.,

3;

S. Elmore,

AbbVie Inc.,

3;

L. Olson,

AbbVie Inc.,

3;

M. L. Giger,
None;

L. C. Wang,

AbbVie Inc.,

3;

M. R. Clark,

AbbVie,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bcl-2-as-a-potential-therapeutic-target-in-human-lupus-tubulointerstitial-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology